News - Appointments

Mission Therapeutics Ltd, which is developing small molecule drugs for neurodegenerative disorders, has promoted Paul Thompson to the position of chief scientific officer, and Nick Edmunds to chief technology officer. The two executives joined Mission in 2016 and 2018 respectively.

CureVac BV, which is developing a messenger RNA (mRNA) vaccine for Covid-19, has appointed Franz-Werner Haas as chief executive and Igor Splawski as chief scientific officer. Both appointments come as the candidate vaccine progresses in the clinic.

Autolus Therapeutics Plc, which is developing cellular immunotherapies for cancer, has appointed Jay Backstrom to its board of directors, and promoted Nushmia Khokhar to senior vice president for clinical development and drug safety. Dr Khokhar joined Autolus in 2017.

The British biotechnology company Mogrify Ltd has appointed Lorenz Mayr to its board of directors. Mogrify works on the development of cell therapies through the discovery of novel cell conversions.

The Dutch genomics company Cergentis BV has appointed Joris Schuurmans as chief executive and Dirk Pollet and Maja Sanders as members of its supervisory board.

Mereo BioPharma Group Plc, which focuses on oncology and rare diseases, has appointed John Lewicki as chief scientific officer, and Ann Kapoun as senior vice president of translational research and develo

Quell Therapeutics Ltd has made two new appointments to its board and announced a new senior vice president for research and translation.

uniQure NV of the Netherlands has announced the appointment of Leonard Post to its board of directors.

The Danish biotechnology company Zealand Pharma A/S has appointed Frank Sanders as president of its US operations.

Scenic Biotech BV of the Netherlands has announced the appointment of Oscar Izeboud as chief executive.